“Those of us in the melanoma business have felt like we ... specifically inhibits the V600E mutant BRAF, a constitutively active kinase present in more than half of metastatic melanomas.

Pfizer only picked up an accelerated approval from the FDA for its Braftovi-based combination regimen for colorectal cancer ...

Vemurafenib (ZELBORAF, Hoffmann-La Roche Inc; Figure 1) is a first-in-class selective inhibitor of the BRAF serine-threonine kinase, FDA approved for the treatment of metastatic melanoma harboring ...

Jedd Wolchok, Stephen Hodi, and Antonio Ribas (from Memorial Sloan-Kettering, Dana-Farber Cancer Institute, and UCLA, respectively), will treat advanced melanoma patients who have a BRAF V600E ...

Already approved in melanoma, Novartis' Tafinlar and Mekinist ... had an effect in patients with BRAF V600E-mutation positive disease. Data presented at the American Society of Clinical Oncology ...

BRAF V600E-mutant metastatic CRC is associated with poor clinical outcomes, with a median overall survival of 17 months. Factors influencing overall survival include metastasectomy and ECOG ...

BRAF mutations occur in approximately 8-12% of cases and are associated with aggressive tumor growth, low efficacy from SOC treatments and a poor prognosis, with a median overall survival less ...

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the progression-free survival (PFS) analysis of the Phase 3 BREAKWATER study of ...

Braftovi, Erbitux, and mFOLFOX6 improved ORR to 60.9% in BRAF V600E-mutated mCRC compared to 40% with mFOLFOX6 alone. The FDA granted accelerated approval for the combination therapy in December 2024, ...